Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2026)

Royalty Pharma has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $648.7 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $648.7 million, up 3523.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $648.7 million (up 3523.87% YoY), and the FY2025 annual result was $577.9 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $648.7 million for Q1 2026 at Royalty Pharma, up from $577.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $648.7 million in Q1 2026 to a low of $900000.0 in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $12.3 million (2023), against an average of $156.0 million.
• Across the five-year window, Other Non-Current Liabilities slumped 80.55% in 2023 and jumped 8913.23% in 2025, its largest moves.
• Royalty Pharma's Other Non-Current Liabilities stood at $2.5 million in 2022, then sank by 64.0% to $900000.0 in 2023, then surged by 520.0% to $5.6 million in 2024, then soared by 10256.09% to $577.9 million in 2025, then rose by 12.25% to $648.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $648.7 million (Q1 2026), $577.9 million (Q4 2025), and $502.9 million (Q3 2025), per Business Quant data.